The brief

Analyst view

• Magnus Medical raised $90.7M including a $25M Series A co-led by Jazz Venture Partners and Red Tree Venture Capital.
• SAINT achieved 510(k) FDA clearance and Breakthrough Device Designation for rapid remission in Major Depressive Disorder.
• The therapy uses fMRI mapping and accelerated theta-burst stimulation (aTBS) for rapid remission in 5 days.

Technical approach

As reported

fMRI Mapping

Personalized neural circuit targeting

SAINT uses functional MRI to map each patient's unique brain circuit patterns, identifying the most effective stimulation target for their depression.

aTBS Protocol

Accelerated theta-burst stimulation

Ten 10-minute sessions per day for 5 days with intelligently timed pulses, achieving remission faster than standard TMS.

Targeting

Adaptive machine learning

Algorithms optimize stimulation site and parameters based on brain response, personalizing treatment in real time.

Outcome

Rapid remission

Clinical trials show 79% remission rate in treatment-resistant depression with median time to remission of 2.6 days, versus 6-9 weeks for standard TMS.

Show all 4